Thu. 29 Feb 2024, 9:12am ET
Benzinga
Biotech, News, FDA, General
Second IND Clearance for ATA3219 Following Non-Hodgkin's Lymphoma (NHL) and First in an Autoimmune Disease Indication
Initial Clinical Data in NHL Anticipated in H2 2024 and for Lupus Nephritis in H1 2025